RxDoctor Payments Data

Neha Kakkar, MD

Internal Medicine · Alma, GANPI 1518318054

Payments from drug & device makers

$3,242in general payments, 2019–2025

Across 116 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$440
  • AbbVie$367
  • Lilly USA, LLC$357
  • Amgen$335
  • Pfizer$288
  • Novo Nordisk$280
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,242100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,242 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$71,587
Medicare patients
204
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide126$146,288
OzempicSemaglutide82$80,103
EliquisApixaban61$55,415
JardianceEmpagliflozin37$42,334
JanuviaSitagliptin Phosphate35$28,390
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,075
LinzessLinaclotide16$8,586
MyrbetriqMirabegron16$8,065
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$7,534
RestasisCyclosporine11$6,679
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,828
VascepaIcosapent Ethyl13$4,574
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen114$3,834
Flovent DiskusFluticasone Propionate14$3,816
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen125$3,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$357$146,288126 claims
Novo NordiskOzempic$280$80,10382 claims
PfizerEliquis$288$55,41561 claims
Boehringer IngelheimJardiance$37$42,33437 claims
AbbVieLinzess, Restasis$367$15,26527 claims
GSKTrelegy Ellipta$102$14,07522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Alma

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →